Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented OrbiMed on the transaction. OrbiMed announced it has raised more than $4.3 billion in commitments for its latest private investment...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented ABS Capital in the deal. ABS Capital announced the closing of its first continuation fund, a GP-led secondary transaction...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer advised Cure Ventures on the deal. Cure Ventures announced the formation of its $350 million inaugural fund. Cure Ventures invests in early-stage life sciences...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Volition Capital on the deal. Volition Capital announced the formation of its $675 million fund, Volition Capital Fund V. The new fund totals over...
You must be a Standard 1 Year member to access this content.
